Treatment Outcomes and Survival of Patients with Gastric Cancer in Hamadan, Iran: A Retrospective Study
Journal of Applied Sciences and Nanotechnology,
2021, Volume 1, Issue 2, Pages 16-26
AbstractThis study aimed to evaluate the effect of various factors and treatments protocols' outcomes on the survival of patients with gastric cancer (GC). In a retrospective cohort study Patients with a definite diagnosis of GC who had been hospitalized at the Mahdie Hospital of Hamadan, Iran, from 2005-2017 were investigated. GC-related survival for different factors, types, locations of the tumor, sites of metastasis, and used treatment methods investigated. Data analyze performed by SPSS software version 21. 95 patients, including 66 (71%) male, and 27 (29%) female, were identified. The mean age was 63.88±12.41 years. The largest proportion of tumors was located in the cardia (29.7%), body (18.9%), and antrum (18.9%) of the stomach. The most common site of metastasis was the liver (52.6%), and lung (26.3%). The average survival of patients was 40.64±4.58 months, and the one, two, three, four, and five years’ survival of investigated patients were 0.68, 0.49, 0.43, 0.39, and 0.34 years, respectively. The average survival of patients with and without metastasis were 16.35±3.27 and 46.97±5.30 months (P=0.004). The Pearson correlation coefficient between the survival and total dose of RT, total number of CT sessions, and dose of each RT session were -0.003 (P-value=0.98), 0.006 (P-value=0.97), and -0.108 (P-value=0.412), respectively. Results show that there were no statistically significant differences between the average survival of patients and used treatment method, grade, type of cancer, and CT medicine. But survival of patients with metastasis was significantly lower than patients without metastasis (P=0.029).
- Article View: 94
- PDF Download: 59